GLP-1 dosing and titration explained: why you start low and step up

If you have looked into starting a GLP-1, you have probably seen phrases like “start low, titrate up” or a chart of doses climbing every few weeks. This guide explains, in plain terms, what titration is and why the FDA labels for these medicines are built around it. This is general education about how the approved labels work. It is not a personal dosing plan. The actual medication, starting dose, and pace of increase are set by a licensed prescriber who knows your history.

What does titration mean for a GLP-1?

Titration simply means starting a medication at a low dose and increasing it in steps over time, rather than beginning at the full “target” dose. For GLP-1 medications, the label schedule usually raises the dose about once every four weeks until you reach a maintenance dose that balances benefit and tolerability.

The reason is comfort and safety, not caution for its own sake. GLP-1 (glucagon-like peptide-1) medicines work in part by slowing how quickly the stomach empties and by acting on appetite signaling, which is also why the most common side effects are gastrointestinal. Starting at a low dose and stepping up slowly gives the digestive system time to adapt, which is how the labels aim to keep nausea, vomiting, diarrhea, and constipation manageable. If you want the fuller picture of those effects, see our guide to GLP-1 side effects and how to manage them, and for the underlying biology, how GLP-1 medications work for weight loss.

Why start low and step up instead of going straight to the full dose?

Two things happen when the dose rises too fast. First, gastrointestinal side effects tend to be worse, which makes people more likely to stop the medication entirely. Second, there is no added benefit to rushing: the target maintenance dose is where the sustained effect lives, and titration is just the on-ramp to get there tolerably. The label schedules exist precisely so that most people can reach a maintenance dose without being knocked out of treatment by side effects along the way.

Slow titration is also why side effects usually ease over time. As the body adapts at each step, symptoms that appear after a dose increase often settle before the next one. A prescriber can also hold you at a given dose longer, or step back down, if a particular increase is not well tolerated. The label pace is a default, not a mandate.

The Wegovy (semaglutide) escalation schedule

The Wegovy injection label sets a fixed five-step escalation to the maintenance dose (Wegovy prescribing information, DailyMed):

For weight reduction, the label’s recommended maintenance dose is 2.4 mg once weekly, with 1.7 mg as an alternative. In March 2026 the FDA approved a higher-dose version, Wegovy HD (semaglutide 7.2 mg), which the label allows as an option to increase to for additional weight reduction (FDA approval announcement). The 7.2 mg dose is the current highest FDA-approved dose for weight management. Reaching it is still a clinical decision, and not everyone needs or is a candidate for it.

The Zepbound (tirzepatide) titration schedule

Zepbound starts everyone at the same low dose and steps up in even increments (Zepbound prescribing information, DailyMed). The label directs starting at 2.5 mg once weekly for 4 weeks, then increasing to 5 mg, with further increases of 2.5 mg allowed after at least 4 weeks on the current dose:

For weight reduction the maintenance doses are 5 mg, 10 mg, or 15 mg once weekly, and 15 mg is the maximum. The 2.5 mg starting dose is described in the label as a starting dose to reduce gastrointestinal side effects, not as a maintenance dose, another example of titration built into the approved schedule.

Who actually decides my dose?

A licensed prescriber does. The schedules above are the FDA-label defaults, but which medication you take, where you start, how fast you move up, when to pause, and what maintenance dose fits you are individualized medical decisions based on your health history, your response, and how you tolerate each step. No honest program hands you a fixed schedule sight unseen, and no page, including this one, can tell you your dose. That supervised, individualized tailoring is also what separates a legitimately low dose set by a clinician from the self-directed GLP-1 microdosing promoted online, which is not an FDA-approved dosing strategy and has no trial evidence behind it for weight loss.

The bottom line

GLP-1 medications are titrated because starting low and stepping up gradually is how the approved labels keep side effects tolerable while you reach an effective maintenance dose. Wegovy climbs in five steps to a 2.4 mg maintenance dose (with a 7.2 mg high-dose option approved in March 2026), and Zepbound climbs in 2.5 mg increments to a maximum of 15 mg. Those schedules are the label framework, not a prescription. A licensed clinician sets the plan that actually fits you.